4P-Pharma, a French clinical stage biotechnology company, and Delta 4, an Austrian digital drug development company, announced the signing of a collaboration agreement.
Under the agreement, both companies will jointly identify and develop first-in-class drug candidates for a rare autoimmune chronic liver disease for which currently no effective curative treatment is available.
Contributing to this collaboration, Delta 4 will apply its proprietary computational and iterative big data analytics platform to identify novel therapeutic targets and signalling pathways as well as drug candidates for a rare autoimmune chronic liver disease. Based on the results provided by Delta 4, 4P-Pharma will structure a tailored R&D maturation program with the focus to further characterize these candidates to demonstrate their potential for improving the treatment. Together, Delta 4
